Table 1.
Demographic and clinical details of RA participants
| Biologic-naïve patients(a) | TNFi-treated patients(b) | p-value | |
|---|---|---|---|
| n = 803 | n = 2154 | ||
| Female, n (%) | 567 (70.6) | 1582 (73.4) | 0.12* |
| Age in yrs, mean (SD) | 61.2 (12.3) | 55.6 (125) | <0.001** |
| Rheumatoid factor positive(c), n (%) | 465/547 (85.0) | 1073/1326 (80.9) | 0.04* |
| No. of prior DMARDs, mean (SD) | 2.5 (1.8) | 4.0 (2.0) | <0.001** |
| Ever used methotrexate, n (%) | 614 (76.5) | 1851 (85.9) | <0.001* |
| Ever used prednisolone, n (%) | 452 (56.3) | 1899 (88.2) | <0.001* |
| HAQ score, mean (SD) | 1.16 (0.79) | 1.37 (0.73) | <0.001** |
| (range 0–3, 0 = no disability) | |||
| AQoL score, mean (SD) | 0.53 (0.27) | 0.49 (0.24) | <0.001** |
| (range 0–1, 1 = full health) | |||
| Joint count, median (range) | 14.5 (0, 59) (n = 286) | 24 (0, 72) (n = 906) | <0.001*** |
| ESR mm/h, median (range) | 26 (1, 129) (n = 263) | 29 (0, 134) (n = 834) | 0.07*** |
| CRP mg/L (median, range) | 8.5 (0.4, 161) (n = 264) | 17 (0.1, 206) (n = 836) | <0.001*** |
| Current smoker, n (%) | 90/776 (11.6) | 300/2111 (14.2) | 0.07* |
| Years since RA diagnosis, mean (SD) | 13.0 (11.3) | 13.7 (10.5) | 0.12** |
| Prior malignancies(d), n (%) | 61 (7.6 %) | 72 (3.3 %) | <0.001* |
(a) data from time first entered into registry unless otherwise indicated; (b) data from time first commenced TNFi treatment; (c) data incomplete: n is shown in table; (d) verified malignancies (excluding NMSC and in-situ cancers) recorded prior to commencement of the study period. HAQ health assessment questionnaire, AQoL assessment of quality of life; ESR erythrocyte sedimentation rate, CRP C-reactive protein.* p-value from Chi-squared test; ** p-value from t-test; *** p-value from Wilcoxon Rank Sum test